Pazopanib Observational Study (PRINCIPAL) - A prospective observational study to capture real world treatment patterns and determine treatment outcomes in patients with advanced or metastatic renal cell carcinoma (RCC) receiving pazopanib.
Phase of Trial: Phase IV
Latest Information Update: 05 Jun 2018
At a glance
- Drugs Pazopanib (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms PRINCIPAL
- Sponsors GlaxoSmithKline; Novartis; Novartis Pharmaceuticals
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 12 Jul 2017 Status changed from recruiting to completed.